Author

J. Korn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:ATAC-seq· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

M. McLaughlin· 2 shared A. Bric· 1 shared A. Frenzel· 1 shared A. Gerstner· 1 shared A. Green· 1 shared A. Hermann· 1 shared A. Koch· 1 shared A. Li· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. McLaughlin

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor specificity

A. Synan, N. C. Wu, R. Velazquez, C. Logel, K. Mueller, A. Green, P. Barzaghi-Rinaudo, Q. Simmons, S. Mercan, X. Shi, J. Korn, M. McLaughlin, W. R. Tschantz, D. Hainzl, A. Malamas, , J. A. D'Alessio

This study develops a bispecific antibody-drug conjugate targeting pCAD and CDH17, showing antitumor activity in dual antigen-expressing tumors but not in single antigen-expressing tumors.

bioRxiv · Apr 19, 2024Cancer Biology

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations

F. Bertoglio, V. Fühner, M. Ruschig, P. A. Heine, L. Abasi, T. Klünemann, U. Rand, D. Meier, N. Langreder, S. Steinke, R. Ballmann, K.-T. Schneider, K. D. R. Roth, P. Kuhn, P. Riese, , M. Hust

The paper describes the selection of a SARS-CoV-2 neutralizing antibody from COVID-19 patients using phage display, showing it binds the ACE2-RBD interface and remains effective against emerging RBD mutations.

Cell Reports · Jul 1, 2021Peer-reviewedBioengineering

In-Depth Characterization and Validation in BRG1-Mutant Lung Cancers Define Novel Catalytic Inhibitors of SWI/SNF Chromatin Remodeling

Z. Jagani, G. Chenail, K. Xiang, G. Bushold, H.-E. C. Bhang, A. Li, G. Elliott, J. Zhu, A. Vattay, T. Gilbert, A. Bric, R. Kikkawa, V. Dubost, R. Terranova, J. Cantwell, , Haas

This study validates novel BRM/BRG1 ATPase inhibitors as chemical probes for SWI/SNF chromatin remodeling and shows their therapeutic potential in BRG1-mut lung cancers.

bioRxiv · Oct 22, 2019 · PreprintCancer Biology